Ankylosing spondylitis trials in Germany

In Germany 14 Also abroad 105

11 of 14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
Where
Bochum, Erlangen
Age
18 years to 65 years
People
140 worldwide
Run by
Grey Wolf Therapeutics
See details and how to joinNCT07047703
Phase 4Not yet taking people in Germany
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Berlin
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
Phase 1Taking people
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Where
Berlin, Hamburg, Ratingen, Wetzlar
Age
18 years and over
People
392 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07290036
Phase 3Taking people
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Where
Berlin, Dresden, Freiburg im Breisgau, Hamburg, Sankt Augustin, Sendenhorst, Tuebingen
Age
2 years to 18 years
People
40 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06668181 · EU 2023-508845-41-00
Phase 1Taking people
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
Where
Herne
Age
18 years and over
People
86 worldwide
Run by
Grey Wolf Therapeutics Limited
See details and how to join2025-521315-39-00
Phase 1Taking people
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Where
Freiburg im Breisgau, Herne
Age
18 years and over
People
20 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06888193 · EU 2024-518689-29-00
No phaseTaking people
Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia.
Where
Erlangen, Hamburg, Hattingen, Marburg, Nuremberg, Würzburg
Age
18 years and over
People
200
Run by
Wuerzburg University Hospital
See details and how to joinNCT07561255
Phase 2Taking people
A Phase 2, open-label, imaging study to explore the effects of sonelokimab in patients with active psoriatic arthritis or axial spondyloarthritis
Where
Erlangen
Age
18 years and over
People
30
Run by
MoonLake Immunotherapeutics AG
See details and how to join2024-514504-13-00
Phase 4Not yet taking people in Germany
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
Where
Herne
Age
18 years and over
People
200 worldwide
Run by
CARE ARTHRITIS LTD.
See details and how to joinNCT07018206 · EU 2025-522118-21-00
Phase 4Taking people
Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis
Where
Herne
Age
18 years and over
People
100
Run by
St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr
See details and how to join2024-513213-13-00
Phase 4Taking people
ToFAcitinib in Early Active Axial SpondyloarThritis:
Where
Berlin
Age
18 years to 45 years
People
104
Run by
Charite University, Berlin, Germany
See details and how to joinNCT06112665